{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-003930","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.718146+00:00","generated_at":"2026-06-19T03:14:21.503732+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kymera reports Q4 2022 net loss $34.9M; cash $559.5M; Sanofi to start KT-474 Phase 2 in 2023","bullets":["Net loss Q4 2022: $34.9M, full year $154.8M; cash and investments $559.5M as of Dec 31, 2022, runway into H2 2025.","Collaboration revenue Q4 $16.1M, full year $46.8M; R&D expenses $43.1M Q4, $164.2M full year.","Sanofi to initiate Phase 2 trial of KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis in 2023.","Phase 1 trials for KT-333 (STAT3) and KT-413 (IRAKIMiD) ongoing; clinical activity data expected in 2023.","KT-253 (MDM2) IND cleared; Phase 1 trial to start early 2023 in solid tumors and hematological malignancies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-003930","json":"https://secwatch.observer/filing/0000950170-23-003930.json","markdown":"https://secwatch.observer/filing/0000950170-23-003930.md","text":"https://secwatch.observer/filing/0000950170-23-003930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023003930/0000950170-23-003930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023003930/kymr-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:14:21.503732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82384d8126652286d72c67a3f062d4354068e260","claim":"Kymera Therapeutics, Inc. reported financial results for the quarter ended December 31, 2022.","evidence_excerpt":"On February 23, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2022 and for the fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023003930/0000950170-23-003930-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ffb541caa4d5b37780a792a25af40e079fd2a23f","claim":"Kymera Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2022.","evidence_excerpt":"On February 23, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2022 and for the fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017023003930/0000950170-23-003930-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}